Summary
Becton Dickinson and Company (BDX) reported solid revenue growth in the third quarter of fiscal year 2024, with total revenues reaching $4.99 billion, a 2.3% increase year-over-year. This growth was driven by strong performance in the Medical and Interventional segments, particularly in Medication Delivery Solutions and Urology and Critical Care, respectively. Net income for the quarter was $487 million, resulting in diluted earnings per share of $1.68, an improvement from $1.36 in the prior year's quarter. The company continues to strengthen its financial position, demonstrated by a significant increase in cash and equivalents and the successful issuance of new debt to fund strategic initiatives. A significant development during the quarter was the announcement of the definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This strategic acquisition is expected to enhance BD's smart connected care solutions and is anticipated to close by the end of calendar year 2024, subject to regulatory approvals. The company also provided updates on ongoing legal matters, including product liability claims and regulatory investigations, noting a $50 million charge related to an SEC investigation into Alaris infusion pumps. Overall, BDX demonstrated resilience and strategic foresight, balancing operational execution with significant growth opportunities.
Financial Highlights
52 data points| Revenue | $4.99B |
| Cost of Revenue | $2.68B |
| Gross Profit | $2.31B |
| R&D Expenses | $299.00M |
| SG&A Expenses | $1.20B |
| Operating Expenses | $4.39B |
| Operating Income | $602.00M |
| Net Income | $487.00M |
| EPS (Basic) | $1.68 |
| EPS (Diluted) | $1.68 |
| Shares Outstanding (Basic) | 289.56M |
| Shares Outstanding (Diluted) | 290.25M |
Key Highlights
- 1Total revenues increased by 2.3% to $4.99 billion in Q3 FY24, driven by strong performance in the Medical and Interventional segments.
- 2Net income rose to $487 million, with diluted EPS improving to $1.68 from $1.36 in the prior-year period.
- 3Announced a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion, expected to close by year-end 2024.
- 4Operating cash flow for the nine months ended June 30, 2024, was robust at $2.67 billion.
- 5The company issued new debt in June 2024 to fund the upcoming acquisition and for general corporate purposes.
- 6Product liability accruals decreased to $1.7 billion as of June 30, 2024, compared to $1.9 billion at September 30, 2023, largely due to settlements and favorable claim resolutions.
- 7Cash and equivalents and short-term investments increased significantly to $5.338 billion as of June 30, 2024.